In this episode, you’ll hear about a new phenotype clinicians have proposed in these guidelines, which is the concept of a non-dilated left ventricular cardiomyopathy phenotype. Dive in to hear more about the updated ESC guidelines on cardiomyopathies with Dr. Juan Pablo Kaski, Consultant Pediatric Cardiologist at Great Ormond Street Hospital (GOSH) and Honorary Associate Professor at the UCL Institute of Cardiovascular Science in London, UK.
First ESC Guidelines on Cardiomyopathies Management
What are the high-risk genotypes and associated predictors of sudden cardiac death? Tune in.
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
In this episode, you’ll hear about a new phenotype clinicians have proposed in these guidelines, which is the concept of a non-dilated left ventricular cardiomyopathy phenotype. Dive in to hear more about the updated ESC guidelines on cardiomyopathies with Dr. Juan Pablo Kaski, Consultant Pediatric Cardiologist at Great Ormond Street Hospital (GOSH) and Honorary Associate Professor at the UCL Institute of Cardiovascular Science in London, UK.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
FINE-HEART Pooled Analysis
<p><span data-teams="true">FINE-HEART Pooled Analysis</span></p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?